Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Payables: 2014-2025

Historic Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $10.1 million.

  • Viridian Therapeutics, Inc.\DE's Payables rose 58.77% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 70.99%. This contributed to the annual value of $2.1 million for FY2024, which is 4.29% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Payables stood at $10.1 million, which was up 18.14% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Payables registered a high of $14.2 million during Q4 2022, and its lowest value of $2.1 million during Q4 2024.
  • Moreover, its 3-year median value for Payables was $3.9 million (2025), whereas its average is $5.0 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Payables skyrocketed by 511.16% in 2022, and later crashed by 84.27% in 2023.
  • Viridian Therapeutics, Inc.\DE's Payables (Quarterly) stood at $2.3 million in 2021, then spiked by 511.16% to $14.2 million in 2022, then plummeted by 84.27% to $2.2 million in 2023, then decreased by 4.29% to $2.1 million in 2024, then soared by 58.77% to $10.1 million in 2025.
  • Its Payables stands at $10.1 million for Q3 2025, versus $8.5 million for Q2 2025 and $3.9 million for Q1 2025.